Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah(The University of Texas MD Anderson Cancer Center), Mimi I. Hu(The University of Texas MD Anderson Cancer Center), Lori J. Wirth(Massachusetts General Hospital), Martin Schüler(Essen University Hospital), Aaron S. Mansfield(Mayo Clinic in Arizona), Giuseppe Curigliano(University of Milan), Marcia S. Brose(University of Pennsylvania), Viola W. Zhu(University of California, Irvine), Sophie Leboulleux(Institut Gustave Roussy), Daniel W. Bowles(University of Colorado Denver), Christina S. Baik(University of Washington), Douglas Adkins(Washington University in St. Louis), Bhumsuk Keam(Seoul National University Hospital), Ignacio Matos(Vall d'Hebron Institute of Oncology), Elena Garralda(Vall d'Hebron Institute of Oncology), Justin F. Gainor(Massachusetts General Hospital), Gilberto Lopes(University of Miami), Chia‐Chi Lin(National Taiwan University Hospital), Yann Godbert(Institut Bergonié), Debashis Sarker(King's College London), Stephen G. Miller(Blueprint Medicines (United States)), Corinne Clifford(Blueprint Medicines (United States)), Hui Zhang(Blueprint Medicines (United States)), Christopher D. Turner(Blueprint Medicines (United States)), Matthew H. Taylor(Providence Portland Medical Center)
Cited by 349
Abstract
Related Papers
No related papers found
Powered by citation graph analysis